ArticleJournal of veterinary science2026
Milbemycin oxime and lotilaner for heartworm prevention in dogs in Korea: a randomized controlled field trial.
Article in Journal of veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
importanceHeartworm disease can lead to chronic cardiopulmonary complications in dogs, and treatment is often prolonged and costly. In Korea,
objectiveThis field study evaluated the effectiveness and safety of a combination of milbemycin oxime and lotilaner (Credelio Plus) for the prevention of heartworm disease in client-owned dogs in the Republic of Korea. DESIGN/SETTING/PATIENTS: This randomized, single-blind, controlled field trial was conducted between June 2023 and February 2024. Client-owned dogs that were at least 8 weeks old, weighed more than 2.0 kg, were walked more than 3 times per week, and tested negative for heartworm at baseline were enrolled.
interventionsThe dogs were allocated in a 1:1 ratio to receive either the investigational veterinary product (milbemycin oxime/lotilaner) or the control veterinary product (milbemycin oxime/afoxolaner) for six consecutive monthly treatments (days 0, 30, 60, 90, 120, and 150). MAIN OUTCOMES AND MEASURES: Prevention of
resultsA total of 53 dogs were enrolled in the study, of which 52 were included in effectiveness and safety analyses. All dogs remained negative for CONCLUSIONS AND RELEVANCE: The results of this study support the use of milbemycin oxime/lotilaner combination as a safe and effective option for the prevention of canine heartworm infections under field conditions in Korea. These findings indicate that this combination product may be a useful option in veterinary parasite control.
trial registrationAnimal and Plant Quarantine Agency, Korea (clinical trial number: A221512).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.